Related Experiment Video
Updated: Jul 15, 2025
06:04
Author Spotlight: Establishment and Confirmation of a Postnatal Right Ventricular Volume Overload Mouse Model
Published on: June 9, 2023
1.1K
Early vvECMO implantation may be associated with lower mortality in ARDS
Peter Rosenberger1, Lisa Korell2, Helene A Haeberle2
1Department of Anesthesiology and Intensive Care Medicine, University Hospital Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany. peter.rosenberger@medizin.uni-tuebingen.de.
Respiratory Research
|September 26, 2023
Summary
Initiating venovenous extracorporeal membrane oxygenation (vvECMO) earlier in severe acute respiratory distress syndrome (ARDS) may reduce mortality. Patients receiving vvECMO within five days of invasive mechanical ventilation (IMV) had lower death rates.
Area of Science:
- Critical Care Medicine
- Respiratory Medicine
- Cardiopulmonary Support
Background:
- Severe acute respiratory distress syndrome (ARDS) often requires advanced respiratory support.
- Venovenous extracorporeal membrane oxygenation (vvECMO) is a key therapy for refractory hypoxemia in ARDS.
- Optimal timing for initiating vvECMO remains an area of clinical uncertainty.
Purpose of the Study:
- To investigate the association between the duration of invasive mechanical ventilation (IMV) before vvECMO initiation and patient mortality.
- To determine if earlier vvECMO support improves outcomes in severe ARDS patients.
Main Methods:
- Retrospective observational study of patients with severe ARDS treated with vvECMO.
- Inclusion of 158 patients from an academic intensive care unit.
- Multivariate logistic regression analysis to assess the impact of IMV duration on 28-day mortality.
Main Results:
- The median duration of IMV before vvECMO was significantly shorter in survivors (1 day) compared to non-survivors (4 days).
- Logistic regression revealed an association between IMV duration and mortality.
- Patients receiving vvECMO within 5 days of IMV had significantly reduced odds of 28-day and in-hospital mortality.
Conclusions:
- Early initiation of vvECMO therapy in severe ARDS patients appears to be associated with reduced mortality.
- Initiating vvECMO within the first 5 days of IMV may be a critical factor for improved survival.
More Related Videos
Related Concept Videos
01:21Acute Respiratory Failure-II
263
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
263
01:23Mechanical Ventilation II: Invasive Ventilation
177
Ventilators are essential medical equipment used to aid patients with respiratory difficulties. Their primary function is to assist or replace spontaneous breathing by providing mechanical ventilation. There are two general classes of mechanical ventilators: negative-pressure and positive-pressure ventilators.
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...
177
01:30Acute Respiratory Failure-III
209
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
209
01:29Acute Respiratory Failure-V
155
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
155
01:29Pulmonary Embolism I: Introduction
7
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
7
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10